With over 1 billion people worldwide classified as obese, the demand for drugs to address this condition is higher than ever before. Novo Nordisk and Eli Lilly, the two most valuable companies in Europe, have developed “miracle” drugs that can help individuals lose a significant portion of their body weight.
These advancements in pharmaceuticals not only have the potential to generate incredible profits for the companies involved but also raise questions about the impact on the global economy. Join hosts Alice Fulwood, Mike Bird, and Tom Lee-Devlin as they explore the implications of these breakthrough drugs on The Economist Podcast. They are joined by guests including Georgia Banjo from The Economist, pharmaceuticals analyst Michael Nedelcovych, and John Cawley, a professor at Cornell University specializing in public policy and economics.
Tune in to The Economist Podcast to stay informed on important topics ranging from global politics and business to science and technology. Subscribe now to gain access to more insightful content. For more details on how to access The Economist Podcasts+, refer to the FAQs page or watch the instructional video on linking your account.
If you require a transcript of the podcast, reach out to the team at [email protected]. The dedication to enhancing accessibility is a top priority, and efforts are underway to expand the availability of podcast transcripts. Don’t miss out on
